Source: Health Times reporter Kong Tianjiao
Since February, a number of well-known pharmaceutical companies have announced their 2021 performance statements.
What are the drugs that these pharmaceutical companies have a high proportion of sales revenue in 2021? What diseases are treated? What products do companies mainly benefit from? The People's Daily health client combed through the reports of Bristol-Myers Squibb, Sanofi, Merck, Roche, and Eli Lilly pharmaceutical companies and found that the drug categories with high sales proportion of different pharmaceutical companies are different.
Among them, Bristol-Myers Squibb's first-line treatment of kidney cell carcinoma, gastric cancer and other drugs O drugs, bringing obvious growth momentum to the enterprise; atopic dermatitis treatment drug dupridosumab is Sanofi's current ace product; Merck's NSCLC, triple negative breast cancer, kidney cell carcinoma, head and neck squamous carcinoma and other diseases K drug, its sales revenue dominates; multiple sclerosis drug Ocrevus has become Roche's best-selling drug; diabetes drug dulagyl peptide is Eli Lilly's current ace product.
Bristol-Myers Squibb:
First-line oncology drug O drug, sales revenue of 7.5 billion US dollars
On February 4, Bristol-Myers Squibb announced its 2021 results, with total revenue of $46.385 billion, up 9% year-on-year.
At present, it can bring significant growth momentum to Bristol-myers Squibb should still be the benchmark product Odivo (navuliyuzumab, O drug, Opdivo), from the 2021 financial results to see the first-line treatment of kidney cell carcinoma, pleural mesothelioma, gastric cancer Odivo has returned to the growth momentum, 2021 sales revenue of 7.523 billion US dollars, an increase of 8% year-on-year.
Bristol-Myers Squibb's business after merging with Celgene focused on three major areas: oncology, haematology and immunity, revlimid (lenalidomide), Eliquis (apixaban), Opdivo (navuliyumab), Orencia (Abasil), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), Yervoy (epilimumab) and Abraxane (albumin paclitaxel) Together, the eight products generated more than $43 billion in sales revenue, accounting for 93 percent of the company's total revenue.
Sanofi:
Atopic dermatitis drug dupridosumab, sales revenue of 5.2 billion euros
On February 4, Sanofi announced its 2021 results, with net income of 37.761 billion euros, an increase of 7.1% year-on-year.
Dupleliumab is Sanofi's current flagship product, with sales revenue up 52.7% year-on-year in 2021 to €5,249 million. Its growth is due to the sustained release of demand from adults, adolescents, and children aged 6-11 years with atopic dermatitis, as well as label expansion and patient penetration in indications for asthma, chronic rhinosinal sinusitis with nasal polyps (CRSwNP). In June 2020, it was approved for the treatment of moderate to severe atopic dermatitis in adults in China and was included in the 2020 edition of the National Medical Insurance Directory, covering more than 30,000 patients. In September 2021, it was approved to expand the use of atopic dermatitis in adolescents over 12 years old in China.
Sanofi's pharmaceutical business focuses on immunoinflammitis, neurological, rare diseases, oncology, diabetes and more. Phase III clinical trials for generalized myasthenia gravis were also initiated in 2021. Sanofi's 2 products under research in the field of rare blood diseases are also worthy of attention.
Merck:
Antineoplastic drug K drug, $17.2 billion
On February 3, Merck announced its 2021 results, with full-year revenue of $48.704 billion, up 17% year-on-year.
The growth of pembolizumab (Keytruda, K drug) is mainly due to the continued penetration and maintenance of a large market advantage in key cancers such as NSCLC, triple-negative breast cancer, renal cell carcinoma, head and neck squamous cell carcinoma, MSH-I, etc., and at the same time, more early first-line drugs have begun to metastasize in clinical drugs.
Merck's business strategy is focused on oncology, cardiovascular/metabolic, immune, infectious diseases, vaccines and other fields, and in addition to the significant contribution of its own star product K drug and cervical cancer vaccine Gardasil/Gardasil9, a large part of its performance growth is more than 20% revenue growth from 3 external cooperation products Lynparza (Olaparza), Lenvima (Lenvatinib), Adempas (Leosil).
Roche:
Multiple sclerosis drug Ocrevus, sales revenue of CHF 5.055 billion
On February 3, Roche announced its 2021 results, with a total annual revenue of CHF 62.801 billion (approximately US$69.012 billion).
Roche Ocrevus is the first drug approved to treat both RRMS and PPMS multiple sclerosis types, with only one injection every 6 months after completing the initial load. In 2021, 8 years of long-term efficacy data for multiple sclerosis were published, showing the consistency of benefits and more favorable to continue the early and continuous treatment of Ocrevus, reaching CHF 5.055 billion in 2021, becoming Roche's best-selling drug and expected to continue to grow in 2022.
Roche's pharmaceutical business focuses on oncology, immunity, neurology, hemophilia, infectious diseases, ophthalmic diseases and other disease areas. Some of the innovative drugs will perform well in 2021, including the hemophilia dual anti-Hemlibra, the new oral spinal muscular atrophy drug Evrysdi (risperlan), the new coronavirus neutralizing antibody Ronapreve, and the Actemra/RoActemra for the treatment of severe pneumonia caused by COVID-19.
Eli Lilly:
Diabetes drug dula glycopeptide, sales revenue of 6.472 billion US dollars
On February 3, Eli Lilly announced its 2021 results, with total revenue of $28.318 billion, up 15% year-on-year. R&D investment was US$7.026 billion, an increase of 15%.
The GLP-1 receptor agonist Trulicity is Eli Lilly's current flagship product, which will continue to maintain a steady growth rate of more than 20% in 2021, with sales revenue reaching $6.472 billion. Suitable for glycemic control in adults with type 2 diabetes mellitus, including monotherapy and patients with poor glycemic control receiving metformin and/or sulfonylurea.
Eli Lilly's current business focuses on four major disease areas: diabetes, oncology, immunity and neurology. The diabetes business has always been the direction of Eli Lilly's advantages and key layout, trulicity (dula glycopeptide), Humulin (recombinant human insulin), Humalog (lispro insulin), Jardiance (empagliflozin) and other 8 product portfolios contributed a total of 13.188 billion US dollars in revenue, accounting for 46.6% of Eli Lilly's total revenue.